Receptor News and Research

RSS

Study links GLP-1 treatment to fewer alcohol drinking days

Current GLP-1 receptor agonist prescriptions were associated with modestly lower AUDIT-C scores in a large, diverse US cohort. The difference appeared to reflect less frequent drinking rather than fewer drinks per occasion or fewer binge-drinking episodes.

13 Jul 2026

Gut microbiota may shape eating behavior and guide new obesity treatments

The review shows how gut microbiota may influence appetite, food reward, inflammation, and energy balance through the gut-brain axis. Microbiota-targeted approaches could support future treatments for obesity and eating disorders, but clinical evidence remains limited.

12 Jul 2026

EGFR inhibitors may overcome chemotherapy resistance in glioblastoma treatment

Treating glioblastoma with a class of drugs known as EGFR inhibitors made this cancer more sensitive to chemotherapy, suggests a study in preclinical models co-led by researchers at UT Southwestern Medical Center and the University of Alabama at Birmingham.

12 Jul 2026

Harvard University hosts the world's largest conference dedicated to longevity biotechnology

The 13th Aging Research & Drug Discovery (ARDD) Meeting, the world's largest conference dedicated to longevity biotechnology, will take place from October 1-3, 2026, at the David Rubenstein Treehouse at Harvard University.

11 Jul 2026

Insurance denials for brand-name drugs surge over past six years

A new study led by researchers at the Johns Hopkins Bloomberg School of Public Health and the American Enterprise Institute found that insurance denials of first attempts to fill prescriptions for brand-name prescription drugs with no generic competitors increased more than two-thirds between 2018 and 2024.

11 Jul 2026

GLP-1RAs linked to lower risk of amputation in diabetes with PAD

Research indicates GLP-1RAs may decrease limb complications in type 2 diabetes with PAD, though more randomized studies are required to confirm efficacy.

10 Jul 2026

GLP-1 exposure in pregnancy does not clearly raise major birth defect risk

A systematic review and meta-analysis of seven cohort studies involving more than 40,000 GLP-1 receptor agonist-exposed pregnancies found no statistically significant increase in major congenital malformations or several other adverse pregnancy outcomes. However, the evidence was low or very low certainty, and a urinary malformation signal based on unadjusted data requires cautious interpretation.

10 Jul 2026

Semaglutide outperforms other GLP-1 drugs for weight loss in psychiatric populations

A network meta-analysis of nine randomized controlled trials found that once-weekly semaglutide showed the largest estimated weight-loss effect among GLP-1 receptor agonists tested in adults with mental illness and obesity or related metabolic risk. The authors cautioned that the findings remain preliminary because the evidence base was small, heterogeneous, and largely indirect.

9 Jul 2026

GLP-1 drugs may reduce lung scarring from Long COVID in diabetic patients

GLP-1 agonists have become popular treatments for weight loss and type 2 diabetes, and newer studies suggest other health benefits as well.

9 Jul 2026

University of Malaga scientists find way to improve morphine treatments

Scientists at the Department of Cell Biology of the University of Malaga have taken a step forward in the search for more effective treatments for pain with a new study that continues advancing in mitigating the addictive effects of morphine -one of the main drugs used for this purpose- as well as the development of analgesic tolerance to this drug.

9 Jul 2026

Researchers identify opioids with highest risk of respiratory depression

University of Manchester researchers have identified which opioids are most likely to be associated with respiratory depression, in a major new study.

9 Jul 2026

Setmelanotide shows promise for hypothalamic obesity after brain tumors

A new therapy helps achieve a healthier BMI in people whose weight has become dysregulated following treatment for a brain tumor, a clinical trial has found.

8 Jul 2026

Study finds growing burden of diabetes-related chronic kidney disease

Chronic kidney disease (CKD) is common, largely silent, and serious. Most people who have the condition do not realize they have it, while it sharply raises the risk of heart attacks, strokes, kidney failure and early death.

8 Jul 2026

New consensus outlines best practices for obesity medications

Obesity and dietitian societies have joined forces to issue a new consensus statement on recommendations surrounding use of obesity drugs for weight loss treatment.

8 Jul 2026

Biohub researchers use artificial intelligence to uncover new psoriasis targets

Biohub researchers performed what they believe is the first genome-wide CRISPR study of primary human adult skin cells, then used an AI model to mine the results for overlooked drug targets for psoriasis.

8 Jul 2026

Investigational drug ameliorates neuronal DNA damage and inflammation in Alzheimer's model

Accumulation of DNA damage in the brain's neurons may contribute to the development of Alzheimer's disease.

8 Jul 2026

Injectable opioid treatment sees rapid growth across the United States

There was a substantial increase in recent years in the use of a form of the primary medication to treat opioid use disorder, according to a Rutgers Health study.

7 Jul 2026

New review shows why antidepressants often fail in Alzheimer’s and Parkinson’s depression

A Molecular Psychiatry review shows that depression in Alzheimer’s and Parkinson’s disease may reflect disease-specific molecular, neurotransmitter, inflammatory, and circuit-level disruptions rather than standard depression biology alone. It argues that broad antidepressants often show limited efficacy in these patients and that future trials should use biomarkers, neuroimaging, and symptom profiling to guide targeted treatments.

7 Jul 2026

Updated ABCs framework gives clinicians a clearer path to prevent heart disease

A 2026 State-of-the-Art review updates the ABCs of cardiovascular disease prevention to help clinicians apply contemporary risk assessment, lifestyle, pharmacologic, and cardiometabolic strategies in routine care. The framework emphasizes PREVENT™ risk equations, Life’s Essential 8, CKM syndrome, obesity care, lipid lowering, blood pressure control, healthy aging, heart failure prevention, and atrial fibrillation management.

7 Jul 2026

Novel leukemia therapy successfully eradicates measurable residual disease

Researchers at The University of Texas MD Anderson Cancer Center were able to eradicate measurable residual disease (MRD) in B-cell acute lymphoblastic leukemia (ALL) patients, a critical step in improving long-term survival outcomes, by treating with the antibody-drug conjugate (ADC) inotuzumab ozogamicin.

7 Jul 2026